NVO - Obesity Solutions Like Weight Loss Drugs To Act As Catalyst For Economic Surge Goldman Sachs Forecasts | Benzinga
Goldman Sachs economists foresee a potential 1% boost to the United States’ Gross Domestic Product (GDP) in the coming years, attributing this surge to the widespread use of weight-loss drugs.
These drugs, known as GLP-1 agonists, are under intense pursuit by various companies, and the market is expected to expand, with the possibility of reaching $100 billion annually by the decade’s end.
Leading the race are Novo Nordisk A/S (NYSE:NVO), the creator of Ozempic, and Eli Lilly (LLY.N), the producer of Mounjaro, Reuters reports.
Citing analysts’ projections, Reuters highlights a significant increase in GLP-1 usage, ranging from 10 ...